ISSN: 1300-7777 E-ISSN: 1308-5263
Ciprofloxacin: a novel therapeutic agent for iron overload? [Turk J Hematol]
Turk J Hematol. 2009; 26(3): 114-117

Ciprofloxacin: a novel therapeutic agent for iron overload?

Mitra Elmi1, Parvaneh Rahimi-moghaddam1, Khosrou Abdi2, Mehdi Shafiee-ardestani2, Massoud Mahmoudian1
1Razi Institute For Drug Research, Tehran, Iran; Department Of Pharmacology, College Of Medicine, Iran University Of Medical Sciences, Tehran, Iran
2Department Of Medicinal Chemistry, College Of Pharmacy, Tehran University Of Medical Sciences, Tehran, Iran

OBJECTIVE: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these chelators are effective, many side effects are reported. In the present study, the iron-chelating effect of ciprofloxacin with good oral absorption was investigated.
METHODS: Thirty male albino Wistar rats were used for the study. Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron. Ciprofloxacin effect on iron absorption in the liver and heart was studied carefully using atomic absorption.
RESULTS: A significant decrease in the liver and heart iron following the ciprofloxacin (14 mg/kg per day) administration was observed, when compared with the control group. This ciprofloxacin-induced tissue iron depletion was more pronounced when it was administered simultaneously with iron, when it was administered for a longer duration (2 months rather than 1 month) and when it was given in higher doses (14 mg/kg per day).
CONCLUSION: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.

Keywords: Thalassemia, iron overload, ciprofloxacin, atomic absorption, chelator


Siprofloksasin: demir yüklenmesi için yeni bir terapötik ajan mı?

Mitra Elmi1, Parvaneh Rahimi-moghaddam1, Khosrou Abdi2, Mehdi Shafiee-ardestani2, Massoud Mahmoudian1
1Razi Institute For Drug Research, Tehran, Iran; Department Of Pharmacology, College Of Medicine, Iran University Of Medical Sciences, Tehran, Iran
2Department Of Medicinal Chemistry, College Of Pharmacy, Tehran University Of Medical Sciences, Tehran, Iran

AMAÇ: Talasemi majör, karaciğer, kalp ve diğer organlarda demir yüklenmesiyle sonuçlanan, çoklu kan transfüzyonları gerektiren hematolojik hastalıklardan biridir. Güncel demir şelasyon tedavisi, intravenöz (IV) defroksamin ve oral deferasiroks ve deferipron uygulamasını içermektedir. Bu şelatörlerin etkili olmalarına karşın, birçok yan etkileri bulunmaktadır. Bu çalışmada, iyi oral absorbsiyonlu siprofloksasinin demir bağlayıcı etkileri araştırılmıştır.
YÖNTEMLER: Bu çalışmada 30 erkek Wistar sıçanı kullanıldı. Siprofloksasin (7 veya 14 mg/kg/gün), demirle aynı zamanda (0.03 g/kg/gün) veya 1 aylık demir uygulaması sonrası uygulanmıştır. Siprofloksasinin karaciğer ve kalpteki demir absorbsiyonu üzerine olan etkisi atomik absorbsiyon kullanılarak dikkatlice çalışılmıştır.
BULGULAR: Kontrol grubuyla karşılaştırıldığında, siprofloksasin uygulamasını (14 mg/kg/gün) takiben karaciğer ve kalp demirinde anlamlı bir düşüş gözlenmiştir. Siprofloksasinle indüklenen bu doku demir deplesyonu yüksek dozda daha belirgindir.
SONUÇ: Siprofloksasin uygulaması, uyumluluğu ve ayrıca talasemik hastaların yaşam beklentisini artırarak, parenteral uygulama yükünü azaltmaya yardımcı olabilir.

Anahtar Kelimeler: Talasemi, demir yüklenmesi, siprofloksasin, atomik absorbsiyon, şelatör


Mitra Elmi, Parvaneh Rahimi-moghaddam, Khosrou Abdi, Mehdi Shafiee-ardestani, Massoud Mahmoudian. Ciprofloxacin: a novel therapeutic agent for iron overload?. Turk J Hematol. 2009; 26(3): 114-117

Corresponding Author: Massoud Mahmoudian, Iran


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686